-       Report 
   - June 2025
    -  150 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                  -       Report 
   - August 2025
    -  120 Pages 
    Global
   
   From       €2287EUR$2,549USD£2,008GBP 
      €2691EUR$2,999USD£2,362GBP 
                -       Report 
   - August 2022
     Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                -       Report 
   - January 2024
    -  200 Pages 
    Global
   
   From       €3724EUR$4,150USD£3,268GBP 
                -       Report 
   - February 2024
    -  112 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                 -       Report 
   - December 2019
    -  356 Pages 
    Global
   
   From       €13456EUR$14,995USD£11,809GBP 
                      Copaxone is a brand of medication used to treat multiple sclerosis (MS). It is a type of central nervous system (CNS) drug, which are used to treat a variety of neurological conditions. Copaxone is a synthetic form of a naturally occurring protein, and is administered as a subcutaneous injection. It is used to reduce the frequency of relapses in people with relapsing-remitting MS.
Copaxone is one of the most widely prescribed MS drugs, and is a major player in the CNS drug market. It is one of the    few drugs approved for the treatment of MS, and is often used in combination with other medications.
The CNS drug market is highly competitive, with many companies offering similar products. Some of the major players in the Copaxone market include Teva Pharmaceuticals, Merck, and Biogen. Other companies in the market include Novartis, Sanofi, and Bayer. Show Less   Read more